NanoMedical Systems

NanoMedical Systems is a private, pre-revenue biotech firm pioneering a novel nanofluidics-based drug delivery platform called nStrada™. Founded in 2009 and headquartered in Austin, Texas, the company is developing subcutaneous implants designed to provide steady, tunable, and long-lasting release of therapeutics from weeks to over a year. Its technology aims to overcome limitations of existing depots, such as burst release and delayed steady-state, and is applicable to a broad spectrum of molecules, including small molecules, peptides, and proteins. The company is currently in the preclinical development stage, advancing multiple generations of its implant system.

nStrada™ nanofluidics platform: A subcutaneous implant using a semiconductor-manufactured chip with precision nanochannels to enable passive, long-term, constant-rate delivery of drugs.

NMS competes with polymer-based depot makers (which have burst release issues), Medici (older technology with moving parts), and MicroCHIPS (power-dependent). Its key differentiators are a passive, solid-state design with no burst effect, constant release, scalable semiconductor manufacturing, and tunability for dose and duration.